Search - tctmd.com

Displaying 21 - 40 of 40

Sort: Relevancy | Date

Presentation TVT 2022

Exercise PVR, A Key Predictor of Benefit of Atrial Shunt Therapy in HFpEF?

Presenter: Sanjiv Shah

June 10, 2022

RELIEVE HF: Different Patient Selection and Study Design – Should We Expect Different Results?

Presentation TVT 2022

Less Invasive Ventricular Enhancement for HFrEF

Presenter: John Boehmer

June 10, 2022

Presentation TVT 2022

What (Else) Have We Learned From REDUCE-LAP II?

Presenter: Sanjiv Shah

June 10, 2022

Presentation TVT 2022

Overview of the Interatrial Shunt Device Landscape: Conceptual Basis and Devices

Presenter: Daniel Burkhoff

June 10, 2022

Presentation TVT 2022

The Alleviant No-Implant Interatrial Shunt for HF: The ALLEVIATE HF1 Trial Results

Presenter: Peter S. Fail

June 10, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for February 2022

Shelley Wood

February 28, 2022

News Conference News THT 2022

Early Positive Signals From RELIEVE-HF Shift Discussion to Atrial Shunt Size

Shelley Wood

February 02, 2022

Presentation THT 2022

Interatrial Shunting in Chronic Heart Failure: Results From the RELIEVE-HF Roll-In Cohort

Presenter: JoAnn Lindenfeld

February 02, 2022

Presentation THT 2022

Alleviant Medical Pivotal Study Overview and Next Steps

Presenter: James Udelson

February 02, 2022

Presentation THT 2022

Alleviant Medical Technology, Procedure and Clinical Data

Presenter: Colin Barker

February 02, 2022

Presentation THT 2022

Clinical Data and Landscape of Interatrial Shunting

Presenter: Peter Fail

February 02, 2022

Presentation THT 2022

Overview of HFpEF Disease State and Physiological Rationale for Atrial Shunting

Presenter: JoAnn Lindenfeld

February 02, 2022

News Industry News

Landmark REDUCE LAP-HF II Trial Demonstrates Clinical Benefit of Corvia Atrial Shunt in Large Segment of Heart Failure Patients

February 02, 2022

News Conference News THT 2022

REDUCE LAP-HF II: Atrial Shunt Device Comes Up Short in HFpEF

Shelley Wood

February 01, 2022

Presentation THT 2022

Putting it into Perspective: Atrial Shunting in the Context of Current Therapies for HFpEF

Presenter: Scott Solomon

February 01, 2022

Presentation THT 2022

Subgroup Analyses of the REDUCE LAP-HF II Study of the Corvia Atrial Shunt

Presenter: Barry Borlaug

February 01, 2022

Presentation THT 2022

REDUCE LAP-HF II Randomized Study of the Corvia Atrial Shunt -- Primary Results

Presenter: Sanjiv Shah

February 01, 2022

Presentation THT 2022

Physiological Rationale and Devices for Interatrial Shunts

Presenter: JoAnn Lindenfeld

February 01, 2022

Presentation THT 2022

CON - Patients with Group 2 Pulmonary Hypertension are not candidates for interatrial shunts!

Presenter: Liviu Klein

February 01, 2022

Presentation THT 2022

PRO - Patients with Group 2 Pulmonary Hypertension are not candidates for interatrial shunts!

Presenter: Roham Zamanian

February 01, 2022

Advertisement

Exercise PVR, A Key Predictor of Benefit of Atrial Shunt Therapy in HFpEF?

Less Invasive Ventricular Enhancement for HFrEF

What (Else) Have We Learned From REDUCE-LAP II?

Overview of the Interatrial Shunt Device Landscape: Conceptual Basis and Devices

The Alleviant No-Implant Interatrial Shunt for HF: The ALLEVIATE HF1 Trial Results

TCTMD’s Top 10 Most Popular Stories for February 2022

Early Positive Signals From RELIEVE-HF Shift Discussion to Atrial Shunt Size

Interatrial Shunting in Chronic Heart Failure: Results From the RELIEVE-HF Roll-In Cohort

Alleviant Medical Pivotal Study Overview and Next Steps

Alleviant Medical Technology, Procedure and Clinical Data

Clinical Data and Landscape of Interatrial Shunting

Overview of HFpEF Disease State and Physiological Rationale for Atrial Shunting

Landmark REDUCE LAP-HF II Trial Demonstrates Clinical Benefit of Corvia Atrial Shunt in Large Segment of Heart Failure Patients

REDUCE LAP-HF II: Atrial Shunt Device Comes Up Short in HFpEF

Putting it into Perspective: Atrial Shunting in the Context of Current Therapies for HFpEF

Subgroup Analyses of the REDUCE LAP-HF II Study of the Corvia Atrial Shunt

REDUCE LAP-HF II Randomized Study of the Corvia Atrial Shunt -- Primary Results

Physiological Rationale and Devices for Interatrial Shunts

CON - Patients with Group 2 Pulmonary Hypertension are not candidates for interatrial shunts!

PRO - Patients with Group 2 Pulmonary Hypertension are not candidates for interatrial shunts!

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content